.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,700,800

« Back to Dashboard

Details for Patent: 5,700,800

Title: Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
Abstract:A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species. The dopamine agonist is administered at the time of, or just after the time of peak plasma prolactin concentration found in lean animals of the same species and the prolactin stimulator is administered at a time just before the plasma prolactin rhythm reaches its peak is lean animals. Insulin resistance, and hyperinsulinemia or hyperglycemia, or both, can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment of obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects.
Inventor(s): Cincotta; Anthony H. (Andover, MA), Meier; Albert H. (Baton Rouge, LA)
Assignee: Ergo Science Incorporated (Charlestown, MA) The Board of Supervisors of Louisiana University and Agricultural and (Baton Rouge, LA)
Filing Date:Oct 31, 1995
Application Number:08/551,064
Claims:1. A method for treating a metabolic condition selected from the group consisting of insulin resistance, hyperinsulinemia, hyperglycemia, and glucose tolerance in an animal or human subject afflicted with said metabolic condition, the method comprising:

administering to said subject an effective amount of a prolactin stimulatory compound on a timed daily basis.

2. The method of claim 1 wherein delivery of said prolactin stimulatory compound is confined to the period during the day after the time at which the serum prolactin concentration of lean, insulin-sensitive subjects of the same species reaches its lowest level and prior to the time of day when said prolactin concentration reaches a peak in lean, insulin-sensitive subjects of the same species.

3. A method for altering body fat stores in an animal or human subject in need of such treatment comprising:

delivering to said subject an effective amount of a prolactin stimulatory compound on a timed daily basis.

4. A method for adhering body weight in an animal or human subject in need of such treatment comprising:

delivering to said subject an effective amount of a prolactin stimulatory compound on a timed daily basis.

5. The method of claim 3 wherein said delivery of said prolactin stimulatory compound is confined to the period during the day after the time at which the serum prolactin concentration of lean, insulin-sensitive subjects of the same species reaches its lowest level and prior to the time of day when said prolactin concentration reaches a peak in lean, insulin-sensitive subjects of the same species, thereby decreasing body fat stores in said subject.

6. The method of claim 3 wherein said delivery of said prolactin stimulatory compound is confined to the period during the day 4 to 8 hours after the time of day at which the serum prolactin concentration of lean, insulin-sensitive subjects of the same species reaches a peak, thereby increasing body fat stores in said subject.

7. The method of claim 4 wherein said administration of said prolactin stimulatory compound is confined to the period during the day after the time at which the serum prolactin concentration of lean, insulin-sensitive subjects of the same species reaches its lowest level and prior to the time of day when said prolactin concentration reaches a peak in lean, insulin-sensitive subjects of the same species, thereby decreasing the body weight of said subject.

8. The method of claim 4 wherein said delivery of said prolactin stimulatory compound is confined to the period during the day 4 to 8 hours after the time of day at which the serum prolactin concentration of lean, insulin-sensitive subjects of the same species reaches a peak, thereby increasing the body weight of said subject.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc